ANIX Share Price | Anixa Biosciences, Inc. Stock Analysis & Recommendation

Q: What does Anixa Biosciences, Inc. do?

Overview: Anixa Biosciences, Inc. is a biotechnology company focused on developing cancer immunotherapy and diagnostic platforms within the Pharmaceuticals & Biotechnology industry.Financial Snapshot: Net Profit: -3 Million (Quarterly Results - Apr 2025) Market cap: USD 118.54 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.97 Return on Equity: -76.26% Price to Book: 7.38Contact Details: Address: 3150 Almaden Expy Ste 250, SAN JOSE CA: 95118 Tel: 1 408 7089808 Fax: 1 302 6555049 Website: https://www.anixa.com/

Q: Who are in the management team of Anixa Biosciences, Inc.?

As of March 2022, the management team of Anixa Biosciences, Inc. includes Dr. Amit Kumar, who serves as the Chairman of the Board, President, and Chief Executive Officer. Additionally, the board features Mr. Lewis Titterton as the Lead Independent Director, along with Dr. Arnold Baskies, Mr. David Cavalier, Ms. Emily Gottschalk, and Dr. John Monahan, all of whom are Independent Directors.

Q: Is Anixa Biosciences, Inc. technically bullish or bearish?

As of 11 September 2025, the technical trend for Anixa Biosciences, Inc. has changed from mildly bullish to sideways. The current stance is neutral, with mixed indicators influencing this position. The weekly MACD is mildly bearish, while the monthly MACD is mildly bullish. The daily moving averages are bullish, but the weekly KST and OBV are both mildly bearish. Bollinger Bands indicate bullishness on both weekly and monthly time frames. In terms of returns, Anixa has outperformed the S&P 500 over the past week (14.24% vs. 1.05%) and month (13.09% vs. 2.33%), but it has underperformed over the longer term, with a 1-year return of -2.32% compared to the S&P 500's 17.14%. Overall, the mixed signals suggest a cautious approach.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

149.67 k

Shareholding (Oct 2025)

FII

1.08%

Held by 13 FIIs

DII

93.76%

Held by 6 DIIs

Promoter

0.00%

How big is Anixa Biosciences, Inc.?

22-Jun-2025

As of Jun 18, Anixa Biosciences, Inc. has a market capitalization of 118.54 million and reported net sales of 0.00 million with a net profit of -12.24 million over the last four quarters. As of Oct 24, the company has shareholder's funds of 20.00 million and total assets of 21.59 million.

View full answer

What does Anixa Biosciences, Inc. do?

22-Jun-2025

Anixa Biosciences, Inc. is a biotechnology company focused on cancer immunotherapy and diagnostics. As of April 2025, it has a market cap of $118.54 million and reported a quarterly net profit loss of $3 million.

View full answer

Who are in the management team of Anixa Biosciences, Inc.?

22-Jun-2025

As of March 2022, Anixa Biosciences, Inc.'s management team includes Dr. Amit Kumar as Chairman, President, and CEO, with Mr. Lewis Titterton as Lead Independent Director and Dr. Arnold Baskies, Mr. David Cavalier, Ms. Emily Gottschalk, and Dr. John Monahan as Independent Directors.

View full answer

Is Anixa Biosciences, Inc. technically bullish or bearish?

20-Sep-2025

As of September 11, 2025, Anixa Biosciences, Inc. shows a neutral trend with mixed indicators, outperforming the S&P 500 in the short term but underperforming over the past year, suggesting a cautious investment approach.

View full answer

Compare Anixa Biosciences, Inc. with Similar Stocks

Cue Biopharma, Inc.NGM Biopharmaceuticals, Inc.Immunome, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 104 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.00

Return on Equity

-72.74%

Price to Book

6.88

Revenue and Profits:

Net Sales:

(Quarterly Results - Oct 2025)

Net Profit:

-3 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-30.73%

6 Months

-15.64%

1 Year

-7.41%

2 Years

-40.22%

3 Years

-39.82%

4 Years

-11.29%

5 Years

-39.29%

Anixa Biosciences, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-8.75%

EBIT to Interest (avg)

-12.63

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.97

Sales to Capital Employed (avg)

0.01

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

18.44%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

5.53

EV to EBIT

-5.58

EV to EBITDA

-5.59

EV to Capital Employed

73.34

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-1314.40%

ROE (Latest)

-76.26%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Oct 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 5 Schemes (5.16%)

Foreign Institutions

Held by 13 Foreign Institutions (1.08%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Oct'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Oct 2025 is 0.00% vs 0.00% in Jul 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Oct 2025 is -17.39% vs 17.86% in Jul 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Oct'25",
        "Jul'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.90",
          "val2": "-2.40",
          "chgp": "-20.83%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.70",
          "val2": "-2.30",
          "chgp": "-17.39%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Oct'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Oct 2025 is 0.00% vs -100.00% in Oct 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Oct 2025 is 13.39% vs -28.28% in Oct 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Oct'25",
        "Oct'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-11.70",
          "val2": "-13.80",
          "chgp": "15.22%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-11.00",
          "val2": "-12.70",
          "chgp": "13.39%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Oct'25 - QoQ

Oct'25

Jul'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-2.90

-2.40

-20.83%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-2.70

-2.30

-17.39%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Oct 2025 is 0.00% vs 0.00% in Jul 2025

Consolidated Net Profit

QoQ Growth in quarter ended Oct 2025 is -17.39% vs 17.86% in Jul 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Oct'25

Oct'25

Oct'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-11.70

-13.80

15.22%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-11.00

-12.70

13.39%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Oct 2025 is 0.00% vs -100.00% in Oct 2024

Consolidated Net Profit

YoY Growth in year ended Oct 2025 is 13.39% vs -28.28% in Oct 2024

All Annual Results

Company CV

About Anixa Biosciences, Inc.

Anixa Biosciences, Inc.

Pharmaceuticals & Biotechnology

Anixa Biosciences, Inc. is a biotechnology company. The Company is developing a cancer immunotherapy program, which leverages chimeric endocrine receptor t-cell (CER-T) technology, and is engaged in developing a diagnostic platform called Cchek, for the early detection of tumor-based cancers. The Cchek liquid biopsy technology is a series of non-invasive blood tests for early detection of solid tumors based on the body's immune response to a malignancy by detecting the presence, absence and quantity of certain immune cells that exist in and around a tumor and that enter the blood stream. This technology enables cancer detection in its earliest stages in efforts to treat patients when the disease is curable. The Company has developed techniques and protocols for measuring the subtle immunological changes that occur in the blood stream during tumor development. Through its protocols, the Company has detected the biomarkers in the peripheral blood of biopsy verified cancer patients.

Company Coordinates

Company Details

3150 Almaden Expy Ste 250 , SAN JOSE CA : 95118

Tel: 1 408 70898081 408 7089808

https://www.anixa.com/

Registrar Details

Anixa Biosciences, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Anixa Biosciences, Inc.?

Watch in Real-Time

What does Anixa Biosciences, Inc. do?

Who are in the management team of Anixa Biosciences, Inc.?

Is Anixa Biosciences, Inc. technically bullish or bearish?

Compare Anixa Biosciences, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Oct 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Oct'25 - QoQ

Annual Results Snapshot (Consolidated) - Oct'25

About Anixa Biosciences, Inc.

Company Coordinates